孕早期母血清甲胎蛋白与缺血性胎盘疾病相关
这项多中心回顾性队列研究纳入1280例有完整记录的孕早期母血清甲胎蛋白筛查患者,发现甲胎蛋白>2.0中位数倍数与子痫前期总体无显著关联,但与缺血性胎盘疾病、胎儿生长受限和早产风险升高相关,并显示孕早期与孕中期甲胎蛋白呈正相关。
要点
- 孕早期甲胎蛋白>2.0中位数倍数与缺血性胎盘疾病风险升高相关(OR 2.26)。
- 孕早期甲胎蛋白升高与胎儿生长受限(OR 3.40)和早产(OR 1.95)风险升高相关。
- 孕早期甲胎蛋白升高与总体子痫前期无显著关联(OR 1.29,95%CI 0.58-2.91)。
核心结论
- 孕早期母血清甲胎蛋白升高与缺血性胎盘疾病、胎儿生长受限和早产相关。
- 这提示孕早期甲胎蛋白升高可能有助于在孕早期识别高危妊娠。
- 未来需研究将孕早期甲胎蛋白加入现有算法能否改善缺血性胎盘疾病的早期检测。
研究设计与样本
- 多中心回顾性队列研究,纳入2015年4月至2017年1月常规孕早期非整倍体筛查中检测孕早期母血清甲胎蛋白的患者。
- 排除多胎妊娠、已知结构或染色体异常、已知恶性肿瘤及分娩记录不完整者。
- 1478例患者中1280例有完整记录可供审查(86.6%)。
主要发现
- 孕早期甲胎蛋白>2.0中位数倍数与总体子痫前期无显著关联(5.8% vs 4.6%,OR 1.29,95%CI 0.58-2.91)。
- 孕早期甲胎蛋白升高组缺血性胎盘疾病发生率15.8% vs 7.7%(OR 2.26,95%CI 1.33-3.87)。
- 孕早期甲胎蛋白升高组胎儿生长受限发生率7.5% vs 2.3%(OR 3.40,95%CI 1.56-7.42)。
- 孕早期甲胎蛋白升高组早产发生率18.3% vs 10.3%(OR 1.95,95%CI 1.18-3.21)。
- 孕早期与孕中期母血清甲胎蛋白呈正相关(rho=0.46,P<.0001)。
关键数值与推荐
- 孕早期母血清甲胎蛋白升高定义为>2.0中位数倍数。
- 采用Fisher精确检验和比值比评估关联,Spearman相关系数评估孕早期与孕中期甲胎蛋白关系。
临床怎么用
- 孕早期母血清甲胎蛋白>2.0中位数倍数可能有助于早期识别缺血性胎盘疾病、胎儿生长受限和早产高危妊娠。
- 孕早期甲胎蛋白与孕中期甲胎蛋白呈正相关,但原文未建议单独用于临床决策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While elevated second-trimester maternal serum alpha fetoprotein has been associated with adverse pregnancy outcomes, the utility of first-trimester maternal serum alpha fetoprotein in predicting these outcomes is limited. Some laboratories have been including maternal serum alpha fetoprotein as part of the first-trimester analyte screening for aneuploidy and preeclampsia, offering its potential utility in predicting pregnancy outcomes. OBJECTIVE: Our primary objective was to determine the association between elevated first-trimester maternal serum alpha fetoprotein and preeclampsia as well as ischemic placental disease (a composite of preeclampsia, fetal growth restriction, and/or placental abruption). Secondary outcomes included early-onset preeclampsia requiring delivery at <34 weeks gestation, fetal growth restriction, placental abruption, preterm delivery, fetal demise, and spontaneous abortion. STUDY DESIGN: An institutional review board-approved multisite retrospective cohort study was performed including all patients with first-trimester maternal serum alpha fetoprotein as part of routine first-trimester aneuploidy screening from April 2015 through January 2017. Pregnancies with multiple gestations, known structural or chromosomal abnormalities, known malignancy, and incomplete delivery records were excluded. Delivery records were reviewed for baseline characteristics and adverse pregnancy outcomes. The optimal cutoff point for first-trimester maternal serum alpha fetoprotein to predict these outcomes was assessed, and an elevated maternal serum alpha fetoprotein was considered >2.0 multiple of the median. A Fisher exact test and odds ratios were used to determine the association between elevated first-trimester maternal serum alpha fetoprotein and adverse pregnancy outcomes. Spearman correlation coefficient assessed the relationship between first- and second-trimester maternal serum alpha fetoprotein. RESULTS: Of 1478 patients with first-trimester maternal serum alpha fetoprotein, 1280 had complete records available for review (86.6%). There was no association demonstrated between elevated first-trimester maternal serum alpha fetoprotein (>2.0 multiple of the median) and the primary outcome, overall preeclampsia (5.8% vs 4.6%, odds ratio, 1.29, 95% confidence interval, 0.58-2.91). However, there was an increased incidence of ischemic placental disease, 15.8% vs 7.7% (odds ratio, 2.26, 95% confidence interval, 1.33-3.87) in those with an elevated alpha fetoprotein. Also, elevated first-trimester maternal serum alpha fetoprotein was associated with a higher incidence of fetal growth restriction (7.5% vs 2.3%, odds ratio, 3.40, 95% confidence interval, 1.56-7.42) and preterm birth (18.3% vs 10.3%, odds ratio, 1.95, 95% confidence interval, 1.18-3.21). Also, a positive correlation between first- and second-trimester maternal serum alpha fetoprotein was demonstrated (rho = 0.46, P < .0001). CONCLUSION: Elevated first-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease, fetal growth restriction, and preterm birth. This suggests that elevated maternal serum alpha fetoprotein may help to identify high risk pregnancies as early as the first trimester of pregnancy. Future studies are necessary to determine whether the addition of first-trimester maternal serum alpha fetoprotein to existing algorithms can improve the early detection of ischemic placental disease.
引用
- Dinglas C, Afsar N, Cochrane E, et al. First-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease. Am J Obstet Gynecol. 2019. PMID: 31794723. doi:10.1016/j.ajog.2019.11.1264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。